U.S. markets closed

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8955-0.0345 (-3.71%)
At close: 04:00PM EDT
0.9402 +0.04 (+4.99%)
After hours: 06:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close0.9300
Bid0.8500 x 1000
Ask0.9400 x 800
Day's Range0.8533 - 1.0000
52 Week Range0.7960 - 4.4000
Avg. Volume98,737
Market Cap27.329M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1220
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ARAV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aravive, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Zacks

    Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

    Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

    Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data.Presented Updated Clinical Data at ASCO Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC); Abstract Selected for Oral Discussion.Continued to Strengthen the Senior Management Team with the Addition of Rudy Howard as Chief Financial Officer and Dr.

  • GlobeNewswire

    Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

    Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academiaHOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer. Dr. Geller is a medical oncologist with over 30 years of drug development experience leading all as